A Phase II study evaluating short course radiation therapy, neoadjuvant bevacizumab, capecitabine and oxaliplatin, and radical resection of primary tumor and metastases in primary stage IV rectal cancer.

Trial Profile

A Phase II study evaluating short course radiation therapy, neoadjuvant bevacizumab, capecitabine and oxaliplatin, and radical resection of primary tumor and metastases in primary stage IV rectal cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Jan 2010

At a glance

  • Drugs Bevacizumab; Capecitabine; Oxaliplatin
  • Indications Cancer metastases; Rectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Nov 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top